Key result
SVT ablation in group 1 PH yields initial success but carries ~18% peri-procedural decompensation risk.
Why the study?
Pulmonary hypertension can lead to supraventricular tachycardias, but the outcomes of catheter SVT ablation in patients with WHO group 1 PH are incompletely characterized.
Does catheter ablation safely and effectively treat supraventricular tachycardia in patients with WHO group 1 pulmonary hypertension?
Cohort (n=38)
No
Does catheter ablation safely and effectively treat supraventricular tachycardia in patients with WHO group 1 pulmonary hypertension?
Catheter ablation for SVT in patients with group 1 pulmonary hypertension is feasible but carries lower initial success rates, higher recurrence rates for certain arrhythmias, and a significant risk of peri-procedural decompensation compared to the general population.
Background: Pulmonary hypertension (PH) is associated with right ventricular pressure overload and atrial remodeling, which may result in supraventricular tachycardias (SVTs). The outcomes of catheter SVT ablation in patients with World Health Organization (WHO) group 1 PH are incompletely characterized. Methods: We conducted a retrospective cohort study of all patients with WHO group 1 PH undergoing catheter SVT ablation during a 10-year period at a major academic tertiary care hospital. Baseline patient characteristics and procedural outcomes at 3 months and 1 year were extracted from the electronic medical record. Results: Ablation of 60 SVTs was attempted in 38 patients with group 1 PH. The initial procedural success rates were 80% for atrial fibrillation (AF, n = 5), 89.7% for typical atrial flutter (AFL, n = 29), 57.1% for atypical AFL (n = 7), 60% for atrial tachycardia (AT, n = 15), and 75% for atrioventricular nodal reentrant tachycardia (AVNRT, n = 4). The 1-year post-procedural recurrence rates were 100% for AF (n = 4), 25% for typical AFL (n = 20), 50% for atypical AFL (n = 2), and 28.6% for AT (n = 7). No patients had recurrent AVNRT (n = 2). There were seven (18.4%) peri-procedural decompensations requiring pressor initiation and transfer to intensive care and one (2.6%) peri-procedural death. Conclusions: The study demonstrates that SVT ablation in group 1 PH can be performed relatively safely and effectively, albeit with lower initial success rates and higher risk of clinical decompensation than in the general population. Recurrence rates at 1 year were higher in AF and atypical AFL ablations and similar for typical AFL and AT ablations when compared to the general population.
No takes yet. Share an insight, caveat, or question.
Satish et al. (2023) conducted a cohort in World Health Organization (WHO) group 1 Pulmonary Hypertension with Supraventricular Tachycardia (n=38). Catheter ablation was evaluated on Initial procedural success and 1-year recurrence rates. Catheter ablation for supraventricular tachycardia in group 1 pulmonary hypertension yielded initial success rates of 57.1% to 89.7% across arrhythmia types, with an 18.4% rate of peri-procedural decompensation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: